Evan Seigerman, an analyst from BMO Capital, maintained the Buy rating on Disc Medicine. The associated price target is $120.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Evan Seigerman has given his Buy rating due to a combination of factors that highlight Disc Medicine’s strategic positioning and potential for growth. The company is making significant strides in its commercialization efforts, particularly with bitopertin, which is moving towards a potential approval and accelerated launch by late 2025 or early 2026. This rapid timeline is supported by the receipt of a Commissioner’s National Priority Voucher, which has allowed the company to expedite its plans and prepare its sales team for targeting patients already undergoing porphyria treatment.
Additionally, Disc Medicine’s pipeline expansion is noteworthy, with plans to initiate trials for DISC-3405 and DISC-0974 in various anemia indications. While there are mixed results in the early data for DISC-0974 in CKD anemia, the potential in MF anemia remains promising. The company’s robust preclinical and early clinical data across its assets, including bitopertin, DISC-0974, and DISC-3405, for treating rare blood disorders, underpins the positive outlook. These factors collectively support the Outperform rating, as they suggest strong potential for future investor interest and market success.
According to TipRanks, Seigerman is a 4-star analyst with an average return of 5.5% and a 48.16% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Novo Nordisk, and Bristol-Myers Squibb.
In another report released on October 17, H.C. Wainwright also reiterated a Buy rating on the stock with a $118.00 price target.